Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in Iowa: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 17 | 483 | 24% |
| 2020 | 14 | 378 | 27% |
| 2021 | 16 | 394 | 30% |
| 2022 | 11 | 354 | 34% |
| 2023 | 10 | 311 | 38% |
| 2024 | 11 | 376 | 40% |
| 2025 from claims | – | 360 291–423 | 41% |
| 2026 forecast | – | 370 290–465 | 40% |
| 2027 forecast | – | 373 277–493 | 40% |
| 2028 forecast | – | 376 266–519 | 41% |
| 2029 forecast | – | 379 258–543 | 41% |
| 2030 forecast | – | 382 250–567 | 42% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 93% of the cases CMS names in Iowa; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 96% inpatient hospital, 4% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 31 | 1,439−3.9%/yr | −3.9%/yr | 1.0 | 0% | 1,600 in 2030+1.8%/yr |
| Ohio | 18 | 1,238−6.8%/yr | −6.8%/yr | 1.1 | 0% | 1,200 in 2030−0.6%/yr |
| Missouri | 24 | 999−5.5%/yr | −5.5%/yr | 1.6 | 0% | 1,110 in 2030+1.7%/yr |
| Michigan | 13 | 961−9.4%/yr | −9.4%/yr | 1.1 | 0% | 870 in 2030−1.7%/yr |
| Indiana | 20 | 960−7.3%/yr | −7.3%/yr | 1.3 | 0% | 930 in 2030−0.5%/yr |
| Wisconsin | 15 | 618−4.6%/yr | −4.6%/yr | 1.1 | 0% | 730 in 2030+2.8%/yr |
| Kansas | 16 | 530−3.8%/yr | −3.8%/yr | 1.3 | 0% | 600 in 2030+2%/yr |
| Minnesota | 6 | 404−8.6%/yr | −8.6%/yr | 0.9 | 0% | 530 in 2030+4.6%/yr |
| Nebraska | 5 | 321−9.6%/yr | −9.6%/yr | 1.2 | 0% | 410 in 2030+4.2%/yr |
| South Dakota | 10 | 315+2.9%/yr | +2.9%/yr | 2.4 | 0% | 470 in 2030+6.9%/yr |
| North Dakota | 3 | 119−14%/yr | −14%/yr | 1.2 | 0% | 380 in 2030+21%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 8 | 1,121−12%/yr | −12%/yr | 2.40.6× | 11% | 1,490 in 2030+4.9%/yr |
| Superficial venous ablation | 16 | 1,064−7.3%/yr | −7.3%/yr | 2.30.7× | 98% | 970 in 2030−1.5%/yr |
| Dialysis access | 15 | 691−12%/yr | −12%/yr | 1.60.3× | 11% | 760 in 2030+1.5%/yr |
| Thrombectomy, IVC filters & venous stents | 1 | 3090%/yr | 0%/yr | 0.70.5× | 0% | 490 in 2030+8.2%/yr |
| Aortic endografts (EVAR/TEVAR) | 1 | 169+0.7%/yr | +0.7%/yr | 0.40.8× | 0% | 210 in 2030+3.4%/yr |
Carotid revascularization in every state, and its device makers · Every procedure market in Iowa · Every state · Compare with Illinois
Boston Scientific leads with 83% of company spending on these surgeons in 2025, −8 pts on 2024.
In 2025, 3 companies reported engagement with Iowa’s surgeons worth $92K in consulting, speaking, meals and travel tied to these products, about $8,402 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.